Literature DB >> 11177118

A separate disease within the syndrome of schizophrenia.

B Kirkpatrick1, R W Buchanan, D E Ross, W T Carpenter.   

Abstract

If schizophrenia is a clinical syndrome rather than a single disease, the identification of specific diseases within the syndrome would facilitate the advance of knowledge and the development of more specific treatments. We propose that deficit psychopathology (ie, enduring, idiopathic negative symptoms) defines a group of patients with a disease different from schizophrenia without deficit features, as the deficit and nondeficit groups differ in their signs and symptoms, course, biological correlates, treatment response, and etiologic factors. These differences cannot be attributed to more severe positive psychotic symptoms or a greater duration of illness in the deficit group. The alternative interpretation that patients with deficit schizophrenia are at the severe end of a single disease continuum is not supported by risk factor and biological features data, but there is a need for independent replication of these findings. We suggest a series of studies designed to falsify one of these hypotheses, ie, multiple diseases vs a single disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11177118     DOI: 10.1001/archpsyc.58.2.165

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  177 in total

1.  Are Negative Symptoms Dimensional or Categorical? Detection and Validation of Deficit Schizophrenia With Taxometric and Latent Variable Mixture Models.

Authors:  Anthony O Ahmed; Gregory P Strauss; Robert W Buchanan; Brian Kirkpatrick; William T Carpenter
Journal:  Schizophr Bull       Date:  2014-11-14       Impact factor: 9.306

2.  Inflammatory markers in antipsychotic-naïve patients with nonaffective psychosis and deficit vs. nondeficit features.

Authors:  Clemente Garcia-Rizo; Emilio Fernandez-Egea; Cristina Oliveira; Azucena Justicia; Miguel Bernardo; Brian Kirkpatrick
Journal:  Psychiatry Res       Date:  2012-03-08       Impact factor: 3.222

3.  Eugen Bleuler and the schizophrenias: 100 years after.

Authors:  Victor Peralta; Manuel J Cuesta
Journal:  Schizophr Bull       Date:  2011-11       Impact factor: 9.306

Review 4.  Functional impairment in people with schizophrenia: focus on employability and eligibility for disability compensation.

Authors:  Philip D Harvey; Robert K Heaton; William T Carpenter; Michael F Green; James M Gold; Michael Schoenbaum
Journal:  Schizophr Res       Date:  2012-04-13       Impact factor: 4.939

Review 5.  Assessment of cognitive insight: a qualitative review.

Authors:  Sally E Riggs; Paul M Grant; Dimitri Perivoliotis; Aaron T Beck
Journal:  Schizophr Bull       Date:  2010-08-06       Impact factor: 9.306

6.  The brief negative symptom scale: psychometric properties.

Authors:  Brian Kirkpatrick; Gregory P Strauss; Linh Nguyen; Bernard A Fischer; David G Daniel; Angel Cienfuegos; Stephen R Marder
Journal:  Schizophr Bull       Date:  2010-06-17       Impact factor: 9.306

Review 7.  Revisiting the diagnosis of schizophrenia: where have we been and where are we going?

Authors:  William R Keller; Bernard A Fischer; William T Carpenter
Journal:  CNS Neurosci Ther       Date:  2010-12-27       Impact factor: 5.243

Review 8.  Avolition and expressive deficits capture negative symptom phenomenology: implications for DSM-5 and schizophrenia research.

Authors:  Julie W Messinger; Fabien Trémeau; Daniel Antonius; Erika Mendelsohn; Vasthie Prudent; Arielle D Stanford; Dolores Malaspina
Journal:  Clin Psychol Rev       Date:  2010-09-18

Review 9.  Motivational Deficits in Schizophrenia and the Representation of Expected Value.

Authors:  James A Waltz; James M Gold
Journal:  Curr Top Behav Neurosci       Date:  2016

10.  Network Analysis Reveals Which Negative Symptom Domains Are Most Central in Schizophrenia vs Bipolar Disorder.

Authors:  Gregory Paul Strauss; Farnaz Zamani Esfahlani; Brian Kirkpatrick; Daniel N Allen; James M Gold; Katherine Frost Visser; Hiroki Sayama
Journal:  Schizophr Bull       Date:  2019-10-24       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.